Sevelamer carbonate 0.8g, 2.4g; per packet; pwd for oral susp. Supplied as opaque, foil-lined, heat-sealed, packets containing 0.8 g or 2.4 g of sevelamer carbonate on an anhydrous basis. 1 Box of ...

We note that Impax’s settlement agreement with Sanofi allows it to sell generic versions of two other products − Renagel and Renvela (for oral suspension) starting on Sep 16, 2014, pending U.S. Food ...

NEW YORK, June 12 (Reuters) - Genzyme Corp said on Friday it received European approval of Renvela, a newer version of its Renagel drug to help control the level of phosphate in the blood of chronic ...

Scottish cost regulators have opened the National Health Service door to Genzyme's Renvela for patients with kidney disease, but turned away Allergan's Botox for migraine and Bayer's contraceptive ...

Impax Laboratories Inc. shares rose 4.4% in premarket trade Tuesday after the company said that its generic Renvela, used to lower phosphorus levels for patients on kidney dialysis, had been approved ...

On October 22, 2007, the US Food and Drug Administration (FDA) granted marketing approval to Genzyme for Renvela, a new treatment for the control of serum phosphorus in patients with chronic kidney ...

Overview: Sevelamer is taken to lower phosphate levels in your blood if you have kidney problems. Common side effects include nausea, vomiting, diarrhea, constipation, upset stomach or stomach pain, ...

Chronic kidney disease (CKD) patients with hyperposphataemia will now have access to a new treatment option in the UK following the launch of Genzyme’s Renvela this week. Chronic kidney disease (CKD) ...

Genzyme Corporation (Nasdaq: GENZ) today announced that the European Commission has approved Renvela® (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease ...

HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation (“Genzyme”) in connection with ...

WASHINGTON Genzyme’s phosphate binder Renvela, used to control serum phosphorus in patients with chronic kidney disease (CKD), has been approved by the Food and Drug Administration. Renvela (sevelamer ...

BOSTON (Reuters) - Genzyme Corp. said on Monday that a powdered version of its experimental kidney disease drug worked as well as an existing Genzyme drug when given three times a day, but did not ...